Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas

Pathobiology

Volumn 76, Issue 6, 2009, Pages 303-314

  Inoue, Keiji ^a   Karashima, Takashi ^a   Kamada, Masayuki ^a   Shuin, Taro ^a   Kurabayashi, Atsushi ^a   Furihata, Mutsuo ^a   Fujita, Hirofumi ^b   Utsumi, Kozo ^b   Sasaki, Junzo ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 aminolevulinic acid; Cancer; Flow cytometry; Photodynamic diagnosis; Protoporphyrin IX; Urothelial lesions

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; AMINOLEVULINIC ACID; BETA ALANINE; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; DEFEROXAMINE; FERROCHELATASE; MANGANESE; NITRIC OXIDE; PROTOPORPHYRIN;

ACCURACY; ARTICLE; CELL MEMBRANE; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INCUBATION TIME; MITOCHONDRION; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRIORITY JOURNAL; PROTEIN METABOLISM; REGULATORY MECHANISM; UROGENITAL TRACT CANCER;

AMINOLEVULINIC ACID; BETA-ALANINE; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DEFEROXAMINE; FERROCHELATASE; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; NITROSO COMPOUNDS; OXIDATIVE PHOSPHORYLATION; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; TIME FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 72449163576     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245896     Document Type: Article

References (44)

1. Utsuki S, Miyoshi N, Oka H, Miyajima Y, Shimizu S, Suzuki S, Fujii K: Fluorescenceguided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study. Brain Tumor Pathol 2007; 24: 53-55.
2. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA, International Society for Photodynamic Therapy in Dermatology: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-143.
3. May A, Ell C: Diagnosis and treatment of early esophageal cancer. Curr Opin Gastroenterol 2006; 22: 433-436.
4. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstädter F, Hofstetter A: Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44: 836-841.
5. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, Knuechel R, Karl A, Tritschler S, Zaak D: Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007; 69: 260-264.
6. Inoue K, Karashima T, Kamada M, Kurabayashi A, Ohtsuki Y, Shuin T: Clinical experience with intravesical instillations of 5-aminolevulinic acid (5-ALA) for the photodynamic diagnosis using fluorescence cystoscopy for bladder cancer. Nippon Hinyokika Gakkai Zasshi 2006; 97: 719-729.
7. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W: Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 67-71.
8. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W: Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A 2003; 42: 1366-1373.
9. Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T: Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5- aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 675-679.
10. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W: Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology 2002; 60: 1025-1028.
11. Lopez RF, Lange N, Guy R, Bentley MV: Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv 2004; 56: 77-94.
12. Kelty CJ, Brown NJ, Reed MW, Ackroyd R: The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci 2002; 1: 158-168.
13. Döring F, Walter J, Will J, Focking M, Boll M, Amasheh S, Clauss W, Daniel H: Delta-aminolevulinic acid transport by intestinal and renal peptiDe transporters and its physiological and clinical implications. J Clin Invest 1998; 101: 2761-2767.
14. Rud E, Gederaas O, Hogset A, Berg K: 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000; 71: 640-647.
15. Rebeiz N, Arkins S, Kelley KW, Rebeiz CA. Enhancement of coproporphyrinogen III transport into isolated transformed leukocyte mitochondria by ATP. Arch Biochem Biophys 1996; 333: 475-481.
16. Hinnen P, De Rooij FW, Terlouw EM, Edixhoven A, Van Dekken H, Van Hillegersberg R, Tilanus HW, Wilson JH, Siersema PD: Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid. Br J Cancer 2000; 83: 539-543.
17. Ohgari Y, Nakayasu Y, Kitajima S, Sawamoto M, Mori H, Shimokawa O, Matsui H, Taketani S: Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. Biochem Pharmacol 2005; 71: 42-49.
18. Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R: Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000; 72: 226-233.
19. Piccinelli P, Samuelsson T: Evolution of the iron-responsive element. RNA 2007; 13: 952-966.
20. Krieg RC, Messmann H, Rauch J, Seeger S, Knuechel R: Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 2002; 76: 518-525.
21. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ, Killion JJ: Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nuDe mice. J Urol 1995; 154: 1532-1538.
22. Fujita H, Utsumi T, Muranaka S, Ogino T, Yano H, Akiyama J, Yasuda T, Utsumi K: Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate- induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 2005; 69: 1773-1784.
23. Ji Z, Yang G, Vasovic V, Cunderlikova B, Suo Z, Nesland JM, Peng Q: Subcellular localization pattern of protoporphyrin IX is an important determinant or its photodynamic efficiency of human carcinoma and normal cell lines. J Photochem Photobiol B 2006; 84: 213-220.
24. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H: Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int J Cancer 2007; 120: 500-505.
25. Calzavara-Pinton PG, Venturini M, Sala R: Photodynamic therapy: update 2006. Part 1: photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007; 21: 293-302. (Pubitemid 46243319)
26. Rud E, Gederaas O, Hogset A, Berg K: 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2006; 71: 640-647.
27. Rodriguez L, Batlle A, Di Venosa G, Battah S, Dobbin P, Macrobert AJ, Casas A: Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells. Br J Pharmacol 2006; 147: 825-833.
28. Juzenas P, Juzeniene A, Moan J: Deferoxamine photosensitizes cancer cells in vitro. Biochem Biophys Res Commun 2005; 332: 388-391.
29. Fadigan A, Dailey HA: Inhibition of ferrochelatase during differentiation of murine erythroleukaemia cells. Biochem J 1987; 243: 419-424.
30. Furukawa T, Adachi Y, Fujisawa J, Kambe T, Yamaguchi-Iwai Y, Sasaki R, Kuwahara J, Ikehara S, Tokunaga R, Taketani S: Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines. Oncogene 2001; 20: 4718-4727.
31. Yamamoto F, Ohgari Y, Yamaki N, Kitajima S, Shimokawa O, Matsui H, Taketani S: The role of nitric oxiDe in delta-aminolevulinic acid (ALA)-induced photosensitivity of cancerous cells. Biochem Biophys Res Commun 2007; 353: 541-546.
32. Datta SN, Loh CS, MacRobert AJ, Whatley SD, Matthews PN: Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma. Br J Cancer 1998; 78: 1113-1118.
33. Navone NM, Polo CF, Frisardi AL, AndraDe NE, Battle AM: Heme biosynthesis in human breast cancer-mimetic 'in vitro' studies and some heme enzymic activity levels. Int J Biochem 1990; 22: 1407-1411.
34. Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, van Hillegersberg R, Tilanus HW, Wilson JH, Siersema PD: Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998; 78: 679-682.
35. Bartosova J, Hrkal Z: Accumulation of protoporphyrin-IX (PpIX) in leukemic cell lines following induction by 5-aminolevulinic acid (ALA). Comp Biochem Physiol C Toxicol Pharmacol 2000; 126: 245-252.
36. Steinbach P, Weingandt H, Baumgartner R, Kriegmair M, Hofstädter F, Knüchel R: Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 1995; 62: 887-895.
37. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstädter F, Hofstetter A: Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44: 836-841.
38. Collaud S, Juzeniene A, Moan J, Lange N: On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents 2004; 4: 301-316.
39. Sharman WM, van Lier JE, Allen CM: Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 2004; 56: 53-76.
40. Inoue A, Muranaka S, Fujita H, Kanno T, Tamai H, Utsumi K: Molecular mechanism of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome and caspase pathway. Free Radic Biol Med 2004; 37: 1290-1299.
41. Piccinelli P, Samuelsson T: Evolution of the iron-responsive element. RNA 2007; 13: 952-966.
42. Kabe Y, Ohmori M, Shinouchi K, Tsuboi Y, Hirao S, Azuma M, Watanabe H, Okura I, Handa H: Porphyrin accumulation in mitochondria is mediated by 2-oxoglutarate carrier. J Biol Chem 2006; 281: 31729-31735.
43. Krishnamurthy P, Xie T, Schuetz JD: The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 2007; 114: 345-358.
44. Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS: Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 2001; 12: 1841-1845.